Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim Pharma Gmbh & Co Kg

Alkahest, Inc.

Gb007, Inc.

Peter Seither

Domnic Martyres

Christoph Hoenke

Matthias Hoffmann

Jan Magnus Kriegl

Riccardo Giovannini

Thorsten K Oost

Ralf Anderskewitz

Horst Dollinger

Thierry Bouyssou

Marc Grundl

Wolfgang Rist

Georg Rast

Birgit Jung

Andreas Weith

Norbert Kraut

Dieter Wolfgang Hamprecht

Pascale Pouzet

Rolf Goeggel

Karl-Heinz Heider

Andreas Zophel

Renate Konopitzky

Hartmut Beug

Silke Hobbie

Barbara Kistler

Horst Johann Ahorn

Martin Jechlinger

Ido M Tamir

Stefan Gruenert

Thomas Waerner

Karsten Quast

Stefan Mueller

Michael Chadham Nivens

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2 antagonistic activity, wherein L, Y, Y, Y, Y, Y, Z, R, R, Rand n have one of the meanings as indicated in the specification and claims, to their use as medicaments, to pharmaceutical compositions containing said compounds and to pharmaceutical compositions containing said compounds in combination with one or more active substances. 

Pyrazole compounds as CRTH2 antagonists

Object of the present invention are novel substituted compounds of the formula 1, wherein A, R, R, Rand Rare defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

Substituted piperidines as CCR3 antagonists

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L, L, X, L, Y, Rand Rare as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.

Pyrazole compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof, wherein R, R, R, R, Y, Y, Y, Y, Y, Z, R, R, n and Rhave one of the meanings as indicated in the specification and claims, to their use as medicaments, to pharmaceutical formulations containing the compounds and to pharmaceutical formulations containing the compounds in combination with one or more active substances.

Therapeutic methods employing substituted piperidines which are CCR3 antagonists

One object of the present invention are novel substituted piperidyl-propane-thiols of the formula (1), wherein R, R, Rand Rare defined as below. Another object of the present invention is to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof. 

Piperidyl-propane-thiol CCR3 modulators

One object of the present invention are novel substituted piperidyl-propane-thiols of the formula (1), wherein R, R, Rand D are defined as below. Another object of the present invention is to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof. 

Substituted piperidyl-propane-thiols

Disclosed are novel piperidine-substituted indoles- or heteroderivatives thereof of the formula 1: wherein R, R, R, R, A, B, D-E, Y, i, j, n and m are defined as below. The compounds of formula 1 are useful as agonists or antagonists of CCR-3. The present invention is also directed to pharmaceutically acceptable salts thereof, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

Piperidine-substituted indoles

The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.

Antibodies to interleukin-like epithelial-mesenchymal transition inducer (ILEI)

The present invention relates to substances which modulate receptors involved in inflammatory processes and whose modulated functions positively influence inflammatory diseases.

Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Growing community of inventors

Biberach, Germany

Peter Seither